mirabegron + propiverine + solifenacin

The combination of **mirabegron**, **propiverine**, and **solifenacin** refers to a therapeutic comparison study involving three distinct oral small-molecule agents used to manage lower urinary tract symptoms (LUTS). This specific grouping is identified in a Phase 3 clinical trial (NCT05490082) conducted by Mansoura University, which evaluates the efficacy of these drugs in patients with non-muscle invasive bladder cancer (NMIBC) experiencing irritative storage symptoms during intravesical BCG therapy. Mirabegron functions as a selective beta-3 adrenergic receptor agonist that relaxes the detrusor muscle to increase bladder capacity. Solifenacin and propiverine are muscarinic receptor antagonists (anticholinergics) that inhibit involuntary bladder contractions by blocking acetylcholine at muscarinic receptors. The trial aims to determine which of these mechanisms or specific agents provides superior symptom relief in the post-BCG setting, where irritative symptoms are a common side effect of treatment.

Brand names

MyrbetriqMictonormVesicare

Other names

mirabegron + propevirine + solifenacin